Public health economics: a systematic review of guidance for the economic evaluation of public health interventions and discussion of key methodological issues

BMC Public Health

Huw Lloyd-Williams¹  Joanna Mary Charles¹  Rhiannon Tudor Edwards¹ 

[1] Centre for Health Economics and Medicines Evaluation, Institute of Medical and Social Care Research, Bangor University, Dean Street Building, Bangor, Gwynedd LL57 1UT, UK

关键词: Outcome measurement;    Inequalities in health;    Public sector policy;    Published guidelines;    Public health;    Health economics;   

Others  :  1161621
DOI  :  10.1186/1471-2458-13-1001

 received in 2013-02-01, accepted in 2013-10-16,  发布年份 2013

【 摘 要 】

Background

If Public Health is the science and art of how society collectively aims to improve health, and reduce inequalities in health, then Public Health Economics is the science and art of supporting decision making as to how society can use its available resources to best meet these objectives and minimise opportunity cost. A systematic review of published guidance for the economic evaluation of public health interventions within this broad public policy paradigm was conducted.

Methods

Electronic databases and organisation websites were searched using a 22 year time horizon (1990–2012). References of papers were hand searched for additional papers for inclusion. Government reports or peer-reviewed published papers were included if they; referred to the methods of economic evaluation of public health interventions, identified key challenges of conducting economic evaluations of public health interventions or made recommendations for conducting economic evaluations of public health interventions. Guidance was divided into three categories UK guidance, international guidance and observations or guidance provided by individual commentators in the field of public health economics. An assessment of the theoretical frameworks underpinning the guidance was made and served as a rationale for categorising the papers.

Results

We identified 5 international guidance documents, 7 UK guidance documents and 4 documents by individual commentators. The papers reviewed identify the main methodological challenges that face analysts when conducting such evaluations. There is a consensus within the guidance that wider social and environmental costs and benefits should be looked at due to the complex nature of public health. This was reflected in the theoretical underpinning as the majority of guidance was categorised as extra-welfarist.

Conclusions

In this novel review we argue that health economics may have come full circle from its roots in broad public policy economics. We may find it useful to think in this broader paradigm with respect to public health economics. We offer a 12 point checklist to support government, NHS commissioners and individual health economists in their consideration of economic evaluation methodology with respect to the additional challenges of applying health economics to public health.

【 授权许可】

   
2013 Edwards et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]National Institute for Health and Care Excellence (NICE): Guide to the methods of technology appraisal. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf webcite
• [2]National Institute for Health and Care Excellence (NICE): Guide to the methods of technology appraisal. http://www.nice.org.uk/media/D45/1E/GuideToMethodsTechnologyAppraisal2013.pdf webcite
• [3]Kelly MP, McDaid D, Ludbrook A, Powell J: Economic appraisal of public health interventions. http://www.cawt.com/Site/11/Documents/Publications/Population%20Health/Economics%20of%20Health%20Improvement/Economic_appraisal_of_public_health_interventions.pdf webcite
• [4]Weatherly H, Drummond M, Claxton K, Cookson R, Ferguson B, Godfrey C, Rice N, Sculpher M, Sowden A: Methods for assessing the cost-effectiveness of public health interventions: key challenges and recommendations. Health Policy 2009, 93:85-92.
• [5]Payne K, McAllister M, Davies LM: Valuing the economic benefits of complex interventions: when maximising health is not sufficient. Health Econ 2012. doi:10.1002/hec.2795 [Published Online First]
• [6]Coast J, Smith R, Lorgelly P: Should the capability approach be applied in health economics? Health Econ 2008, 17:667-670.
• [7]Drummond M, Weatherly H, Claxton K, Cookson R, Ferguson B, Godfrey C, Rice N, Sculpher M, Sowden A: Assessing the Challenge of Applying Standard Methods of Economic Evaluation to Public Health Interventions. http://phrc.lshtm.ac.uk/papers/PHRC_D1-05_Final_Report.pdf webcite
• [8]Wanless D: Securing good health for the whole population: Final report. http://webarchive.nationalarchives.gov.uk/+/http:/www.hm-treasury.gov.uk/media/D/3/Wanless04_summary.pdf webcite
• [9]Owen L, Morgan A, Fischer A, Ellis S, Hoy A, Kelly M: The cost-effectiveness of public health interventions. J Public Health 2011. doi: 10.1093/pubmed/fdr075 [Published Online First]
• [10]Woolf SH, Husten CG, Lewin LS, Marks JS, Fielding JE, Sanchez EJ: The economic argument for disease prevention: distinguishing between value and savings. http://www.prevent.org/data/files/initiatives/economicargumentfordiseaseprevention.pdf webcite
• [11]The Cabinet Office: A Guide to Social Return on Investment. http://www.thesroinetwork.org/publications/cat_view/29-the-sroi-guide-2009?orderby=dmdate_published&ascdesc=DESC webcite
• [12]Liberati A, Altman DG, Tetzlaff J, Mulrows C, Gøtzsche PC, Ioannidis JPA, Clarke M, Deveraux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009, 6:e1000100.
• [13]MacDonald G, O’Hara K: Ten elements of mental health, its promotion and demotion: implications for practice. London: Society of Health Education and Promotion Specialists; 1998.
• [14]Culyer AJ: The normative economics of health care finance and provision. Oxf Rev Econ Policy 1989, 5:34-58.
• [15]Sen AK: Commodities and Capabilities. Oxford: Oxford University Press; 1985.
• [16]Camerer CF, Lowenstein G: Behavioural economics: past present and future. http://www.hss.caltech.edu/~camerer/ribe239.pdf webcite
• [17]Astolfi R, Lorenzoni L, Oderkirk J: A Comparative Analysis of Health Forecasting Methods. : OECD Health Working Papers, No. 59, OECD Publishing; 2012. http://dx.doi.org/10.1787/5k912j389bf0-en webcite
• [18]Morris S, Devlin N, Parkin D: Economic Analysis in Healthcare. Chichester, UK: Wiley and Sons; 2007.
• [19]Gyrd-Hansen D: Willingness to pay for a QALY: theoretical and methodological issues. Pharmacoeconomics 2005, 23:423-432.
• [20]Group EQL: EuroQoL—a new facility for the measurement of health related quality of life. Health Policy 1990, 16:199-208.
• [21]Grewal I, Lewis J, Flynn T, Brown J, Bond J, Coast J: Developing attributes for a generic Quality of Life Measure for Older People: preferences or capabilities? Soc Sci Med 2006, 62:1891-1901.
• [22]HM Treasury: The Green Book: Appraisal and Evaluation in Central Government. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/220541/green_book_complete.pdf webcite
• [23]Byford S, McDaid D, Sefton T: Because it’s worth it: a practical guide to conducting economic evaluations in the social welfare field. http://www.jrf.org.uk/sites/files/jrf/1859351123.pdf webcite
• [24]Tarn TY, Smith MD: Pharmacoeconomic guidelines around the world. ISPOR Connections 2004, 10:4-5.
• [25]National Institute for Health and Clinical Excellence (NICE): Methods for the development of NICE public health guidance. http://www.nice.org.uk/media/CE1/F7/CPHE_Methods_manual_LR.pdf webcite
• [26]National Institute for Health and Clinical Excellence (NICE): Supporting Investment in Public Health: Review of Methods for Assessing Cost Effectiveness, Cost Impact and Return on Investment. http://www.nice.org.uk/media/664/AC/cost_impact_proof_of_concept.pdf webcite
• [27]Brenzel L: Selecting an Essential Package of Health Services using Cost-Effectiveness Analysis: A Manual for Professionals in Developing Countries. http://pdf.usaid.gov/pdf_docs/PNACJ346.pdf webcite
• [28]Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, Murray CJL: World Health Organisation guidance to cost-effectiveness analysis. http://www.who.int/choice/publications/p_2003_generalised_cea.pdf webcite
• [29]Honeycutt AA, Clayton L, Khavjou O, Finkelstein EA, Prabhu A, Blitstein JL, Evans WD, Renaud JM: Guide to Analysing the Cost-Effectiveness of Community Public Health Prevention Approaches. http://aspe.hhs.gov/health/reports/06/cphpa/report.pdf webcite
• [30]Mont D, Loeb M: Beyond DALYs: Developing Indicators to Assess the Impact of Public Health Interventions on the Lives of People with Disabilities. http://siteresources.worldbank.org/SOCIALPROTECTION/Resources/SP-Discussion-papers/Disability-DP/0815.pdf webcite
• [31]Sassi F, Hurst J: The Prevention of Lifestyle-Related Chronic Diseases: An Economic Framework. http://www.oecd.org/health/healthpoliciesanddata/40324263.pdf webcite
• [32]Medical Research Council: Guidance on the development, evaluation and implementation of complex interventions to improve health. http://www.mrc.ac.uk/Utilities/Documentrecord/index.htm?d=MRC004871 webcite
• [33]Sen AK: Capability and Well-being. In The Quality of Life. Edited by Nussbaum MC, Sen AK. Oxford: Clarendon Press; 1993.
• [34]Marsh K, Phillips CJ, Fordham R, Bertranou E, Hale J: Estimating cost-effectiveness in public health: a summary of modelling and valuation methods. Health Econ Rev 2012., 2doi:10.1186/2191-1991-2-17 [Published Online First]
• [35]Diener E: Subjective well-being. Psychol Bull 1984, 95:542-575.
• [36]Williams A: Cost-benefit analysis: bastard science? And/or insidious poison in the body politick? J Public Econ 1972, 1:199-225.
• [37]Sackett DL, Rosenberg WMC, Muir Gray JA, Haynes RB, Richardson WS: Evidence based medicine: what it is and what it isn't. BMJ 1996, 312:71-72.
• [38]Williams A: Priorities and research strategy in health economics for the 1990. Health Econ 1993, 2:295-302.
• [39]Phelps CE: Perspectives in health economics. Health Econ 1995, 4:335-353.
• [40]Fuchs VR: The future of health economics. J Health Econ 2000, 19:141-157.
• [41]Edwards RT: Paradigms and research programmes: is it time to move from health care economics to health economics? Health Econ 2001, 10:635-649.
• [42]Chokshi DA, Farley TA: The cost-effectiveness of environmental approaches to disease prevention. N Engl J Med 2012, 367:295-297.
• [43]Drummond MF, Stoddart GL, Torrance GW: Methods for the Economic Evaluation of Health Care Programmes. 3rd edition. Oxford: Oxford University Press; 2005.
• [44]Edwards RT, Céilleachair A, Bywater T, Hughes DA, Hutchings J: A parenting programme for children at risk of developing conduct disorder: a cost-effectiveness analysis. BMJ 2007, 334:682.
• [45]Edwards RT, Hounsome B, Linck P, Russell IT: Economic evaluation alongside pragmatic randomised trials: developing a Standard Operating Procedure for clinical trials units. Trials 2008, 14:64-65.
• [46]Edwards RT, Neal RD, Linck P, Bruce N, Mullock L, Nelhans N, Pasterfield D, Russell D, Russell I, Woodfine L, on behalf of the CHARISMA study group: Enhancing ventilation in homes of children with asthma: cost-effectiveness study alongside randomised trial. Br J Gen Pract 2011, 61:733-741.
• [47]Murphy S, Edwards RT, Williams N, Raisenen L, Moore G, Linck P, Hounsome N, Ud Din N, Moore L: An evaluation of the effectiveness and cost effectiveness of the National Exercise Referral Scheme in Wales, UK: a randomised controlled trial of a public health policy initiative. J Epidemiol Community Health 2012, 66:745-753.